Floatz logo

Gm-Csf

Immunodeficiencies

New York Medical CollegePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

9 Active assets in the Immunodeficiencies cohort.

Asset / SponsorPhaseRating
Thiotepa
University of California, San Francisco
Phase 2BB
Cyclophosphamide
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2BB
Busulphan
University of California, San Francisco
Phase 2BB
Evomela
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2BB
FILGRASTIM
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2BB

View all 14 →

Same molecule, other indications

Gm-Csf is also rated in:

melanomaDormant
BBB
Indicative ·
74 / 100
View asset →
acute lymphoblastic leukemiaDormant
BBB
Indicative ·
74 / 100
View asset →
uveal melanomaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →